Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

3(43%)

Results Posted

150%(3 trials)

Terminated

1(14%)

Phase Distribution

Ph phase_1

14%

Ph early_phase_1

14%

Ph not_applicable

14%

Ph phase_2

43%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Early Phase 1First-in-human

1(16.7%)

Phase 1Safety & dosage

1(16.7%)

Phase 2Efficacy & side effects

3(50.0%)

N/ANon-phased studies

1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(2)

Terminated(2)

Detailed Status

Completed2

Recruiting2

Withdrawn1

Terminated1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (16.7%)

Phase 11 (16.7%)

Phase 23 (50.0%)

N/A1 (16.7%)

Trials by Status

completed229%

recruiting229%

withdrawn114%

terminated114%

active_not_recruiting114%

Recent Activity

3 active trials

Showing 5 of 7

active_not_recruitingphase_1

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

NCT05627245

recruitingphase_2

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

NCT06572618

recruitingphase_2

Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study

NCT05077735

terminated

Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer

NCT03053960

completednot_applicable

Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA

NCT02989623

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT05627245Phase 1

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Active Not Recruiting

NCT06572618Phase 2

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

Recruiting

NCT05077735Phase 2

Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study

Recruiting

NCT03053960

Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer

Terminated

NCT02989623Not Applicable

Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA

Completed

NCT03513952Phase 2

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Completed

NCT05111314Early Phase 1

Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma

Withdrawn

All 7 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 7